Two new lung cancer trials open in Australia
The Australasian Lung Cancer Trials Group (ALTG), an initiative of Lung Foundation Australia, is a multi-disciplinary organisation dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers and improving the quality of life of patients, carers and families through the coordination and facilitation of high quality clinical research.
The ALTG has opened two new trials, the DREAM study (ALTG 15/004) and NIVORAD study (ALTG 14/002), exploring potential new treatments in mesothelioma and advanced non-small cell lung cancer (NSCLC). In the DREAM study patients with mesothelioma receive the immunotherapy, Durvalumab in combination with chemotherapy. The NIVORAD study is exploring whether radiation therapy can increase the activity of the immunotherapy, Nivolumab in treating patients with advanced NSCLC.
If the treatment approaches being tested in DREAM and NIVORAD are found to be safe and show some benefit, this will enable larger studies to be designed to more fully test the benefits of combining immunotherapy with chemotherapy for patients with mesothelioma or combining immunotherapy with radiation therapy for patients with advanced NSCLC. For more information contact email@example.com.